Subcutaneous Administration of Natalizumab Can Lead to Lower Drug Concentrations Than Intravenous Administration
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis and Related Disorders
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration
Mult Scler Relat Disord 2024 Jul 30;90(xx)105796, LMY Gelissen, S Loveless, AA Toorop, J Howlett, FC Loeff, T Rispens, J Killestein, EC Tallantyre, ZLE van KempenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.